title: All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality.
abstract: The year 2014 marked the beginning of the end of the interferon era and the triumph of the all-oral interferon-free regimens for treatment of hepatitis C virus (HCV) infection. These innovative therapies are safe and yield a cure rate of over 90%. The scientific hepatology community is euphoric about the possibility of elimination and even eradication of HCV infection. However, the current high cost of the new all-oral regimens allows access to treatment only for a restricted number of HCV-infected patients. In addition, many other conditions such as modality of access and delivery of care, inadequate knowledge of HCV epidemiology and political commitments to be undertaken, hamper the fulfillment of the dream to eliminate the virus. Since, such conditions are not impossible to overcome, a global urgent effort must be made to allow a widespread access to the new treatments which will permit in the next years to avoid million of HCV-related deaths.
authors.affiliation: Luigi E Adinolfi, Barbara Guerrera, Department of Medical, Surgical, Neurological, Geriatric and Metabolic Sciences, Second University of Naples, 80100 Naples, Italy.
authors.forename: Luigi E
authors.initials: LE
authors.lastname: Adinolfi
authors.affiliation: Luigi E Adinolfi, Barbara Guerrera, Department of Medical, Surgical, Neurological, Geriatric and Metabolic Sciences, Second University of Naples, 80100 Naples, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Guerrera
keywords: Daclatasvir; Dasabuvir; Ledipasvir; New-oral hepatitis C virus treatments; Ombitasvir; Paritaprevir; Simeprevir; Sofosbuvir